Xenetic Bioscience

Xenetic Biosciences is a biopharmaceutical company that specializes in the development of innovative cancer therapies and drug delivery solutions. Its primary focus is on advancing XCART, a personalized chimeric antigen receptor T cell platform designed to target specific tumor neoantigens in patients. The company is also engaged in creating cell-based therapeutics that specifically target B-cell receptors on malignant tumor cells, particularly for the treatment of B-cell lymphomas. Additionally, Xenetic is developing a DNase platform aimed at enhancing existing treatments by addressing neutrophil extracellular traps, which are linked to cancer progression and treatment resistance. The company is collaborating with major pharmaceutical partners, including Takeda Pharmaceutical, to leverage its proprietary PolyXen drug delivery platform, enhancing the efficacy and performance of various therapeutics. Headquartered in Framingham, Massachusetts, Xenetic Biosciences is dedicated to advancing the field of oncology through its innovative research and development efforts.